⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNYSE

CRL

Charles River Laboratories International, Inc.

Healthcare · Diagnostics & Research

278.35USD

-2.4100 (-0.86%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Loading security description…
A first visit to a security takes a few seconds.

Charles River Laboratories International, Inc.

Ticker CRL · NYSE
Healthcare »Research »
Classification Diagnostics & Research

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

1)

Price Chart

GP »

Price

 

 

1M6MYTD1Y5Y
Close
Px/Chg 1D (USD)278.35 / -0.86%
52 Wk H (08/24/26)298.58
52 Wk L (09/25/25)145.57
YTD Change/%81.28 / 40.7%
Mkt Cap (USD)13.4B
Shrs Out/Float48.2M / 47.2M
SI/% of Float2.4M / 5.7%
Days to Cover2.5
2)

Estimates

EE »
Next Report11/04/26
P/E—
Est P/E 12/202621.94
T12M EPS (USD)-4.80
Est EPS12.69
Est PEG0.12
Analyst Target$281.00
3)

Dividend

DVD »
Ind Gross Yield—
Ind Ann Dvd (USD)—
5Y Avg Yield—
Cash—
Payout Ratio0.0%
Ex-Dvd Date—
4)

Total Return

COMP »
1M+4.96%
3M+47.89%
6M+67.75%
1Y+73.31%
3Y+40.56%
5Y-36.62%
52W vs SPX+83.18% / +17.48%
Beta1.41
5)

Trading

HP »
Day Range275.00 - 280.23
Prev Close280.76
Volume0.8M
Avg Volume0.9M
50d Avg255.93
200d Avg200.74
Employees18,300

Dated 52-week rows are the highest and lowest CLOSE and the day each happened, which sits a little inside the intraday range a vendor quotes. Quotes are refreshed once a night — during a session the price above is the previous close.